SCHEMBL3093093

SCHEMBL3093093

CCOC(=O)C(Cc1cnn(Cc2ccccc2)c1)C(=O)NS(=O)(=O)c1ccc2ccccc2c1

nearest known ligand 0.43

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MMP8 P22894 1/20 0.43
LARS1 Q9P2J5 1/20 0.43
PKM P14618 1/20 0.41
ALDH1A1 P00352 3/20 0.41
TP53 P04637 1/20 0.41
GAA P10253 1/20 0.40
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
PLG P00747 1/20 0.40
F2 P00734 2/20 0.39
LMNA P02545 1/20 0.39
SCD O00767 1/20 0.38
SCD5 Q86SK9 1/20 0.38
RAPGEF3 O95398 1/20 0.38
NPY1R P25929 1/20 0.38
NPY2R P49146 1/20 0.38
PLAU P00749 1/20 0.38
PLAT P00750 1/20 0.38
KAT6A Q92794 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3470358 0.90 LARS1 (0.46) LARS1ALDH1A1KMT2AF2LMNA
SCHEMBL3090643 0.87 LARS1 (0.43) LARS1ALDH1A1KMT2APLGF2
SCHEMBL3091388 0.86 MMP8 (0.58) MMP8LARS1PKMALDH1A1TP53
SCHEMBL3096206 0.85 LARS1 (0.41) LARS1ALDH1A1MEN1KMT2APLG
SCHEMBL3097141 0.83 BCHE (0.39) LARS1ALDH1A1PLGSCDSCD5
SCHEMBL3093166 0.83 LARS1 (0.41) LARS1ALDH1A1MEN1KMT2APLG
SCHEMBL27972264 0.83 MMP8 (0.39) MMP8PKMALDH1A1TP53KMT2A
SCHEMBL3093748 0.82 LARS1 (0.54) MMP8LARS1ALDH1A1TP53GAA
SCHEMBL3085046 0.81 MMP8 (0.48) MMP8LARS1ALDH1A1MEN1KMT2A
SCHEMBL3091802 0.81 GAA (0.47) ALDH1A1GAAF2LMNASCD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2172450-B9 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF MITSUBISHI TANABE PHARMA CORP (JP) 2014-10-08 EP disclosed
EP-2172450-B1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF MITSUBISHI TANABE PHARMA CORP (JP) 2013-10-16 EP disclosed
US-8461209-B2 Malonic acid sulfonamide derivative and pharmaceutical use thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2013-06-11 US disclosed
US-20100228026-A1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF MITSUBISHI TANABE PHARMA CORPORATION (JP) 2010-09-09 US disclosed
EP-2172450-A1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF Mitsubishi Tanabe Pharma Corporation (JP) 2010-04-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100228026-A1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF REN, AGTR2, AGTR1 MMP8 3060/4885LARS1 1976/4885PKM 1468/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.